Stocktoria
Black Diamond Therapeutics, Inc. BDTX
Black Diamond Therapeutics, Inc. (BDTX) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $70.0M at a 32.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.816 |
| Retained earnings / assets | -3.25 |
| EBIT / assets | 0.088 |
| Equity / liabilities | 3.643 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 3/9 | -1.13 | — | +26.9% |
| AUTL | Autolus Therapeutics plc | 2/9 | -6.27 | — | +644.9% |
| CSBR | CHAMPIONS ONCOLOGY, INC. | 5/9 | -7.27 | — | +4.4% |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
FAQ
Is BDTX financially healthy?
Black Diamond Therapeutics, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does BDTX pay a dividend?
No, Black Diamond Therapeutics, Inc. does not currently pay a dividend.
How profitable is BDTX?
In FY2025, Black Diamond Therapeutics, Inc. had a net margin of 32.0% and a return on equity of 19.9%.
What is BDTX's P/E ratio?
Black Diamond Therapeutics, Inc.'s trailing price-to-earnings (P/E) ratio is about 4.4×, based on its latest annual earnings.
What is the analyst price target for BDTX?
The average Wall-Street price target for Black Diamond Therapeutics, Inc. is $9.86, about 369.4% above the recent price, from 7 analysts.
Is BDTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Black Diamond Therapeutics, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 4.4×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.